India, Nov. 4 -- Septerna, Inc. (SEPN), a clinical-stage biotechnology company focused on G protein-coupled receptor (GPCR) drug discovery, announced the selection of SEP-204 as a potential first-in-class development candidate for Graves' disease and thyroid eye disease (TED). The company also reported initial preclinical findings ahead of a poster presentation at the 2026 American Thyroid Association Annual Meeting on November 5.
SEP-204 is an investigational oral small-molecule thyroid-stimulating hormone receptor (TSHR) negative allosteric modulator designed to block receptor overactivation caused by disease-driving autoantibodies.
Preclinical studies demonstrated potent and selective TSHR inhibition, including reduced activation by th...